ERBB2 and invasive breast carcinoma: In early breast cancer, HER2-directed therapies are approved for the treatment of patients with HER2-positive invasive breast cancer as defined by HER2 protein overexpression, or HER2 gene amplification with HER2/CEP17 ratios ≥2.2.